Liver tumor-promoting effect of beta-naphthoflavone, a strong CYP 1A1/2 inducer, and the relationship between CYP 1A1/2 induction and Cx32 decrease in its hepatocarcinogenesis in the rat
T. Shoda et al., Liver tumor-promoting effect of beta-naphthoflavone, a strong CYP 1A1/2 inducer, and the relationship between CYP 1A1/2 induction and Cx32 decrease in its hepatocarcinogenesis in the rat, TOX PATHOL, 28(4), 2000, pp. 540-547
Interrelationships among induction of cytochrome P-450 (CYP) 1A1/2, decreas
e in connexin 32 (Cx32), and liver tumor-promoting activity by beta-naphtho
flavone (BNF) in the promotion stage were examined in a 2-stage liver carci
nogenesis model. A total of 20 male Fischer 344 rats were initiated with a
single intraperitoneal injection of 150 mg/kg of diethylnitrosamine (DEN) o
r were given the saline vehicle alone. Starting 2 weeks later, they were fe
d a diet containing 2%, 1%, or 0% BNF for 6 weeks. All animals were subject
ed to a two-thirds partial hepatectomy at week 3 and were sacrificed at wee
k 8. Absolute and relative liver weights were significantly increased in th
e DEN+BNF groups as compared to the DEN-alone group. Diffuse hepatocellular
hypertrophy with cytoplasmic eosinophilia, sometimes accompanied by develo
pment of adenoma-like hepatic foci, was observed in the BNF-treated rats. R
emarkable induction of cytochrome CYP 1A1/2 and significant increase in CYP
2E1 were noted in the DEN+BNF groups, and positive immunohistochemical sta
ining for both was observed diffusely. The areas of Cx32-positive spots per
hepatocyte in the centrilobular areas of livers of the BNF-treated rats we
re significantly decreased, but no changes were observed in periportal area
s. The numbers and areas of foci positive for glutathione S-transferase pla
cental form were increased in the BNF-treated groups. These results suggest
that BNF is a liver tumor promoter that, unlike phenobarbital, does not in
duce CYP 2B1/2 isozymes, and there seems to be no direct relationship betwe
en CYP 1A1/2 induction and Cx32 reduction in BNF hepatocarcinogenesis.